ES2043607T3 - Agentes fibrinoliticos modificados. - Google Patents

Agentes fibrinoliticos modificados.

Info

Publication number
ES2043607T3
ES2043607T3 ES86810518T ES86810518T ES2043607T3 ES 2043607 T3 ES2043607 T3 ES 2043607T3 ES 86810518 T ES86810518 T ES 86810518T ES 86810518 T ES86810518 T ES 86810518T ES 2043607 T3 ES2043607 T3 ES 2043607T3
Authority
ES
Spain
Prior art keywords
fibrinolytic agents
modified
modified fibrinolytic
glycosylation
sites
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES86810518T
Other languages
English (en)
Inventor
Bhabatosh Dr Chaudhuri
Bernd Dr Meyhack
Jutta Dr Heim
Oostrum Jan Dr Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Application granted granted Critical
Publication of ES2043607T3 publication Critical patent/ES2043607T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

NUEVAS PROTEINAS T-PAS HUMANAS SE HAN ENSAYADO. ESTAS NUEVAS T-PAS SON APROPIADAS COMO FIBRINOLITICO EN LA N-GLICOXILACION.
ES86810518T 1985-11-18 1986-11-13 Agentes fibrinoliticos modificados. Expired - Lifetime ES2043607T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB858528321A GB8528321D0 (en) 1985-11-18 1985-11-18 Modified fibrinolytic agents

Publications (1)

Publication Number Publication Date
ES2043607T3 true ES2043607T3 (es) 1994-01-01

Family

ID=10588363

Family Applications (1)

Application Number Title Priority Date Filing Date
ES86810518T Expired - Lifetime ES2043607T3 (es) 1985-11-18 1986-11-13 Agentes fibrinoliticos modificados.

Country Status (17)

Country Link
EP (1) EP0225286B1 (es)
JP (1) JPS62272976A (es)
KR (1) KR920007666B1 (es)
AT (1) ATE78514T1 (es)
AU (1) AU598490B2 (es)
DE (1) DE3686136T2 (es)
DK (1) DK174977B1 (es)
ES (1) ES2043607T3 (es)
FI (1) FI91160C (es)
GB (1) GB8528321D0 (es)
GR (1) GR3006041T3 (es)
IE (1) IE57866B1 (es)
IL (1) IL80659A (es)
NO (1) NO175266C (es)
NZ (1) NZ218305A (es)
PT (1) PT83752B (es)
ZA (1) ZA868689B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES8702945A1 (es) * 1984-10-01 1987-01-16 Integrated Genetics Inc Un metodo de producir activador de plasminogeno de tejido uterino humano
ATE74379T1 (de) * 1985-12-23 1992-04-15 Chiron Corp Peptidplasminogenaktivatoren.
US5258298A (en) * 1986-01-31 1993-11-02 Genetics Institute, Inc. Deletion and glycosylation mutant of human tissue plasminogen activator
US5837518A (en) * 1986-01-31 1998-11-17 Genetics Institute, Inc. Thrombolytic proteins
US5002887A (en) * 1986-01-31 1991-03-26 Genetics Institute, Inc. Truncated thrombolytic proteins
US5589361A (en) * 1986-03-18 1996-12-31 Genentech, Inc. Human tissue-type plasminogen activator variant
IE81073B1 (en) * 1986-03-18 2000-01-12 Genentech Inc Modified human tissue-type plasminogen activator and its preparation
US5047241A (en) * 1986-07-11 1991-09-10 American Home Products Corporation Tris-Kringle plasminogen activator with novel K2 insert
EP0276846A3 (en) * 1987-01-29 1989-07-26 Zymogenetics, Inc. Colony-stimulating factor derivatives
JPH084501B2 (ja) * 1987-03-20 1996-01-24 エーザイ株式会社 糖鎖に関する変異ｔＰＡ
US6682733B1 (en) * 1987-06-18 2004-01-27 Roche Diagnostics, Gmbh Fibrinolytic enzymes
SE8702562L (sv) * 1987-06-18 1988-12-19 Kabigen Ab Nya fibrinolytiska enzymer
US5266474A (en) * 1987-06-24 1993-11-30 Genentech, Inc. Balanced inducible transcription system
US5302390A (en) * 1987-07-01 1994-04-12 Beecham Group Plc Hybrid proteins of human plasminogen and human t-PA, pharmaceutical compositions and methods of treatment
AU2081788A (en) * 1987-07-06 1989-01-30 Genetics Institute Inc. Novel thrombolytic proteins
AU1893988A (en) * 1987-07-13 1989-01-19 Collaborative Research Inc. Nonglycosylated plasminogen activator and method of preparation
US5270198A (en) * 1988-05-20 1993-12-14 Genentech, Inc. DNA molecules encoding variants of tissue plasminogen activators, vectors, and host cells
IL90146A (en) * 1988-05-20 1994-10-07 Genentech Inc Glycosylation derivatives of tissue plasminogen activator
US5346824A (en) * 1988-05-20 1994-09-13 Genentech, Inc. DNA encoding variants of tissue plasminogen activators and expression vectors and hosts thereof
US5258180A (en) * 1988-09-02 1993-11-02 Genetech, Inc. Tissue plasminogen activator having fibrin specific properties and deletion of amino acids 466-970, compositions and methods of treatment
US5714145A (en) * 1988-09-02 1998-02-03 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties
US5262170A (en) * 1988-09-02 1993-11-16 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties and substituted at amino acid positions 296-299, DNA molecules encoding them, vectors, and host cells
US5108901A (en) * 1988-09-02 1992-04-28 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties
WO1991015235A1 (en) * 1990-03-30 1991-10-17 Survival Technology, Inc. t-PA ENHANCER PROFILE
US5242688A (en) * 1990-12-24 1993-09-07 Eli Lilly And Company Method of treating thromboembolic disorders by administration of diglycosylated t-pa variants
JP3559559B2 (ja) * 1992-06-03 2004-09-02 ジェネンテク，インコーポレイテッド 向上した治療特性を有する組織プラスミノーゲン活性化因子グリコシル化変異体
WO1995004823A1 (en) * 1993-08-04 1995-02-16 Ciba-Geigy Ag High molecular weight desulphatohirudin
US6706504B1 (en) 1996-11-12 2004-03-16 The Scripps Research Institute Tissue type plasminogen activator (t-PA) variants: compositions and methods of use
SG11201408028YA (en) * 2012-06-14 2015-01-29 Portola Pharm Inc METHOD FOR PURIFICATION OF RECOMBINANT FACTOR Xa DERIVATIVES

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR79202B (es) * 1982-05-05 1984-10-22 Genentech Inc
SU1662352A3 (ru) * 1982-05-05 1991-07-07 Генентек, Инк (Фирма) Штамм бактерий ЕSснеRIснIа coLI - продуцент активатора плазминогена тканевого типа
WO1984001786A1 (en) * 1982-10-28 1984-05-10 Beecham Group Plc Enzyme derivatives and their use in the treatment of thrombosis
AU572108B2 (en) * 1983-01-19 1988-05-05 Genentech Inc. Human tpa production using vectors coding for dhfr protein
ES8702945A1 (es) * 1984-10-01 1987-01-16 Integrated Genetics Inc Un metodo de producir activador de plasminogeno de tejido uterino humano
DE3537176C2 (de) * 1984-10-18 1994-06-09 Zymogenetics Inc Gewebeplasminogenaktivator und Verfahren zu seiner Herstellung
JPH0811066B2 (ja) * 1985-09-30 1996-02-07 インテグレーテッド・ジエネティックス・インコーポレーテッド 組換えｄｎａが生産するヒト子宮プラスミノ−ゲンアクチベ−タ−

Also Published As

Publication number Publication date
DK549186D0 (da) 1986-11-17
IL80659A0 (en) 1987-02-27
JPS62272976A (ja) 1987-11-27
EP0225286B1 (en) 1992-07-22
ATE78514T1 (de) 1992-08-15
PT83752A (en) 1986-12-01
DK549186A (da) 1987-05-19
FI91160C (fi) 1994-05-25
DE3686136D1 (de) 1992-08-27
NO175266C (no) 1994-09-28
GR3006041T3 (es) 1993-06-21
FI91160B (fi) 1994-02-15
KR920007666B1 (ko) 1992-09-14
ZA868689B (en) 1987-06-24
NO864569L (no) 1987-05-19
NO175266B (no) 1994-06-13
IL80659A (en) 1991-12-15
IE863028L (en) 1987-05-18
IE57866B1 (en) 1993-05-05
AU6520086A (en) 1987-05-21
FI864654A (fi) 1987-05-19
EP0225286A2 (en) 1987-06-10
EP0225286A3 (en) 1987-10-07
NO864569D0 (no) 1986-11-17
KR870005094A (ko) 1987-06-04
AU598490B2 (en) 1990-06-28
DK174977B1 (da) 2004-04-05
GB8528321D0 (en) 1985-12-24
PT83752B (pt) 1989-06-30
DE3686136T2 (de) 1992-12-17
NZ218305A (en) 1990-01-29
FI864654A0 (fi) 1986-11-14

Similar Documents

Publication Publication Date Title
ES2043607T3 (es) Agentes fibrinoliticos modificados.
GR78180B (es)
DK275788A (da) Fibrinolytiske proteiner
BR8906843A (pt) Composicao alvejante liquida
DK43387D0 (da) Fibrinolytisk enzym
DK165687A (da) Modificeret fibrinolytisk enzym
DK165787A (da) Modificeret fibrinolytisk enzym
FI864552A (fi) Human-lysozym.
GR3004556T3 (es)
DK165987A (da) Modificeret fibrinolytisk enzym
DE59003161D1 (de) STABILISIERUNG VON GLYKOSYLIERTEM t-PA.
DK491988D0 (da) Modificerede plasminogen-aktivatorer
DK459088A (da) Plasminogenaktivatorer
ATE119940T1 (de) Gewebs-plasminogen-aktivator-derivat.
ES1002496Y (es) Accionamiento regulador de depresion
NO922262D0 (no) Forbedret fibrinolytisk blanding
MC1856A1 (fr) Composition fibrinolytique
BR8401730A (pt) Homogeneizador e quarteador de minerio-mhq 01
FI854760A (fi) Foerfarande foer homogenisering av braenslefloedet under matningen.
BR8400042A (pt) Tunel de aeracao
KR880014007U (ko) 모니터의 수직편향 출력회로

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 225286

Country of ref document: ES